India’s Department of Pharmaceuticals has stopped Abbott (NYSE:ABT) from pulling its Xience Alpine drug-eluting coronary stent from the market.
The move is a reversal from the National Pharmaceutical Pricing Authority’s decision last month to allow Abbott to withdraw the device over a one-year period.
Get the full story at our sister site, Drug Delivery Business News.
The post India pulls an about-face on Abbott’s Xience Alpine stent appeared first on MassDevice.